CHRM4

Across TCGA pan-cancer cohorts, CHRM4 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated CHRM4 data layer compared with 8 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher CHRM4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRM4 expression acts as an unfavorable survival marker, although some lineages such as LGG and LUAD show a favorable association.

ACC, LGG, and LUAD are the cancer types where CHRM4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.242	0.648	<.001	95	view →
LGG	DFS	Median	All	0.830	0.647	<.001	54	view →
LUAD	DFS	Median	II,III,IV	0.570	0.313	<.001	36	view →
MESO	OS	Median	All	0.445	0.633	.006	34	view →
BLCA	DFS	Quartile	All	0.475	0.649	.004	32	view →
CHOL	DFS	Tertile	II,III,IV	0.754	0.105	.006	32	view →
KIRC	OS	Median	All	0.585	0.717	.011	28	view →
OV	OS	Quartile	All	0.266	0.416	.003	24	view →
UCEC	OS	Median	III,IV	0.862	0.785	.006	24	view →
BRCA	DFS	Median	III,IV	0.924	0.830	.004	22	view →
SKCM	OS	Quartile	II,III,IV	0.412	0.308	.009	19	view →
PAAD	OS	Tertile	All	0.523	0.237	.009	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

CHRM4–ACC (DFS)

Open the ACC breakdown →